Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MK-8242 |
Synonyms | |
Therapy Description |
MK-8242 binds MDM2 and prevents its interaction with p53, thereby inhibiting degradation of p53 and potentially resulting in increased tumor cell apoptosis (PMID: 30253242). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MK-8242 | SCH 900242 | MDM2 Inhibitor 23 | MK-8242 binds MDM2 and prevents its interaction with p53, thereby inhibiting degradation of p53 and potentially resulting in increased tumor cell apoptosis (PMID: 30253242). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | liposarcoma | predicted - sensitive | MK-8242 | Phase I | Actionable | In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with advanced solid tumors, particularly those with TP53 wild-type liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and a median progression-free survival in LPS of 237 days (PMID: 28240971). | 28240971 |
TP53 wild-type | Advanced Solid Tumor | unknown | MK-8242 | Phase I | Actionable | In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with TP53 wild-type advanced solid tumors, particularly those with liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and 75.6% (31/41) of patients achieving stable disease (PMID: 28240971). | 28240971 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|